goat anti mouse igg2a human ads hrp secondary antibody  (SouthernBiotech)

Journal: bioRxiv

Article Title: Dirty mice better recapitulate key features of mRNA vaccine immunogenicity observed in humans

doi: 10.64898/2026.03.07.709392

Figure Lengend Snippet: mRNA vaccination in dirty mice requires booster vaccination and is less durable than in SPF mice. (A) Model for generating and vaccinating dirty mice, days (d) indicated. (B–E) Serum antibody responses in SPF (black) and dirty (red) mice. Illustration generated with images from NIAID NIH BioArt. (B) Anti-S1 RBD IgG levels over 61 days post-vaccination (N=48), expressed as area under the curve (AUC) from serial dilution ELISAs (OD 405 ). (C) Quantification of serum IgG specific to SARS-CoV-2 WT Spike (AU/ml) through day 151 post-immunization. (D) Neutralizing antibody titers over 61 days post-vaccination, expressed as FRNT 50 . (E) Cross-reactive serum IgG levels against SARS-CoV-2 Spike variants (WT, BA.1, BA.5) at day 61 (AU/ml). Data represent individual mice with mean ± SEM; p-values determined by Welch’s T-test 2 . (F) Antibody clearance from serum of mock-injected (N=3) and α’NP-injected SPF (N=4) and dirty mice (N=4), expressed as α’NP IgG2a AUC. N=3-4 AUC values per timepoint are represented on the graph aside from mock d59 with N=2, with standard deviation indicated. Antibody levels in B, C, and E were determined using MSD-ECLIA. Antibody levels in F were determined with ELISA.

Article Snippet: Serum was diluted 1:100 in dilution buffer prior to serial 1:4 dilutions, and Goat Anti-Mouse IgG2a Human ads-HRP secondary antibody (SouthernBiotech) was used as the secondary antibody for detection.

Techniques: Generated, Serial Dilution, Injection, Standard Deviation, Enzyme-linked Immunosorbent Assay

Journal: bioRxiv

Article Title: Dirty mice better recapitulate key features of mRNA vaccine immunogenicity observed in humans

doi: 10.64898/2026.03.07.709392

Figure Lengend Snippet: The dirty mouse model is stable over time and season. (A) Percent of mice in each cohoused cohort that were seropositive for murine pathogens. Data corresponds to mice shown in . Only pathogens with seropositivity among the mice are depicted, additional pathogens tested in panel are listed in Materials and Methods. (B) Correlation of T cell activation status (percent of CD44+-hi expressing cells among CD8a+ T cells) with anti-S1 RBD IgG levels at 60 days post-prime (30 days post-boost). Antibody levels are represented as AUC. N=21 mice. Linear regression model equation and 95% confidence interval is shown on graph. (C) Multidimensional scaling (MDS) analysis of serology panel data from cohoused mice. Each dot represents a dirty laboratory mouse. Distance between points represents similarity of pathogen exposure history. Points are colored by the year that the experiment occurred. Data is representative of N=1014 mice. (D) Comparison of average percent CD44+-Hi among CD8a+ T cells (left) and average pathogen richness (right) from mice in panel C across seasons. Error bars represent standard deviation. (E) Experimental design used to generate the double co-housed dirty mouse model. Illustration generated with images from NIAID NIH BioArt. (F) Heatmaps of seroprevalence against a panel of murine pathogens in single co-housed (60 days) and double co-housed (120 days) mice. Squares are divided into triangles representing data from two independent experimental replicates. (G) Frequency of activated CD8a+/CD44-Hi T cells in single and double co-housed mice assessed at days 60 and 121. Bars represent mean ± SEM. (H) Anti-S1 RBD IgG log10 endpoint titers (OD 405 ) 30 days post-prime and -booster (N=20) in SPF (black), single (red), and double (purple) co-housed mice. Data represent individual mice with horizontal bars indicating mean and brackets indicate fold-change relative to SPF. Antibody levels in panels B and H were determined using ELISA.

Article Snippet: Serum was diluted 1:100 in dilution buffer prior to serial 1:4 dilutions, and Goat Anti-Mouse IgG2a Human ads-HRP secondary antibody (SouthernBiotech) was used as the secondary antibody for detection.

Techniques: Activation Assay, Expressing, Comparison, Standard Deviation, Generated, Enzyme-linked Immunosorbent Assay

Journal: Journal of Extracellular Vesicles

Article Title: Engineered Low‐Endotoxin Bacterial Biomimetic Vesicles for Enhanced Oral Dual‐Antigen Subunit Vaccine Delivery

doi: 10.1002/jev2.70207

Figure Lengend Snippet: Engineering and immunological action mechanism of COS‐coated BBVs for oral dual‐antigen delivery. (A) Schematic illustration of GDH‐gD‐Fc‐CSS‐BBV@COS preparation. (B) COS‐coated GDH‐gD‐Fc‐CSS‐BBV@COS traverses the epithelial barrier and significantly reduce the inflammatory response, stimulate macrophages and epithelial cells within lamina propria and initiate adaptive immune responses. GDH‐gD‐Fc‐CSS‐BBV@COS is preferentially captured by microfold (M) cells in the Peyer's patches. Processed antigens are subsequently presented by mature dendritic cells (DCs) to naive T cells, driving differentiation into T helper 1 (Th1), T helper 2 (Th2) and cytotoxic CD8⁺ T cells. Simultaneously, naive B cells are activated in the B cell follicles, triggering the germinal centre reaction, plasma cell differentiation and antibody production (including IgG and dimeric IgA). Key cytokines involved (IFN‐γ, IL‐4) and secretory IgA (sIgA) transport are indicated.

Article Snippet: Goat HRP‐conjugated anti‐mouse IgG1 (1071‐05) and goat HRP‐conjugated anti‐mouse IgG2a (1080‐05) antibodies were purchased from Southern Biotech (Birmingham, AL, USA).

Techniques: Clinical Proteomics, Cell Differentiation

Journal: Journal of Extracellular Vesicles

Article Title: Engineered Low‐Endotoxin Bacterial Biomimetic Vesicles for Enhanced Oral Dual‐Antigen Subunit Vaccine Delivery

doi: 10.1002/jev2.70207

Figure Lengend Snippet: Oral administration maximizes in vivo delivery of mCherry‐CSS‐BBV@COS and induces specific antibody responses. (A) Schematic diagram of in vivo and ex vivo fluorescence imaging of BALB/c mice at different time intervals after mCherry‐CSS‐BBV@COS administration via various routes. (B) Examples of in vivo fluorescence scans performed within 24 h after oral or intramuscular administration of mCherry (30 µg) or mCherry‐CSS‐BBV@COS (containing 30 µg mCherry) to mice. (C) Examples of ex vivo imaging of different organs performed 24 h after administration. (D, E) Summary graphs of experiments in vivo (D) and ex vivo (E). (F) Scheme of the immunization experiment. The mice were immunized with 30 µg of vaccine (mCherry content) via intramuscular injection and oral administration on Day 0, followed by a booster immunization on Day 14. Serum levels of specific IgG and sIgA were detected using indirect ELISA. (G) Serum levels of IgG against mCherry, LPS and OMPs. Data are presented as OD 450 values. (H) Levels of sIgA against mCherry in vaginal secretions. Data are presented in µg/mL.

Article Snippet: Goat HRP‐conjugated anti‐mouse IgG1 (1071‐05) and goat HRP‐conjugated anti‐mouse IgG2a (1080‐05) antibodies were purchased from Southern Biotech (Birmingham, AL, USA).

Techniques: In Vivo, Ex Vivo, Fluorescence, Imaging, Injection, Indirect ELISA

Journal: Journal of Extracellular Vesicles

Article Title: Engineered Low‐Endotoxin Bacterial Biomimetic Vesicles for Enhanced Oral Dual‐Antigen Subunit Vaccine Delivery

doi: 10.1002/jev2.70207

Figure Lengend Snippet: Induction of antigen‐specific antibody responses in mice by GDH‐gD‐Fc‐CSS‐BBV@COS. (A) Schematic diagram of the immunization, blood and vaginal secretion sampling procedures. (B–E) Determination by iELISA of the levels of IgG against GDH (B), gD (C), LPS (D) and OMPs (E) in sera after 50× dilution presented as OD 450 values. (F–I) Determination by iELISA of the levels of IgG1 and IgG2a against GDH (F), gD (G), LPS (H) and OMPs (I) in sera after 50× dilution presented as OD 450 values. (J) The levels of sIgA against GDH, gD, LPS and OMP in vaginal secretion determined using iELISA and presented in µg/mL.

Article Snippet: Goat HRP‐conjugated anti‐mouse IgG1 (1071‐05) and goat HRP‐conjugated anti‐mouse IgG2a (1080‐05) antibodies were purchased from Southern Biotech (Birmingham, AL, USA).

Techniques: Sampling

Journal: Immunity

Article Title: COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge

doi: 10.1016/j.immuni.2021.06.018

Figure Lengend Snippet:

Article Snippet: Goat Anti-Mouse IgG2a, Human ads-HRP antibody , SouthernBiotech , 1080-05, RRID: AB_2734756.

Techniques: Purification, Blocking Assay, Activation Assay, Marker, Virus, Recombinant, Staining, Luciferase, Cell Culture, Lysis, Transfection, Polymer, Stable Transfection, Cell Surface Receptor Assay, Software